Articles On Memphasys (ASX:MEM)

By Tim Boreham, Editor ASX code: ((HYD)) Market cap: $4.3m Shares on issue: 254,218,847 Financials (December half 2023): revenue $5.97m (down -17.5%), loss of $3.82m (-$1.96m deficit previously), cash of $847,277 (down -73.5%)* * After bala...

The ASX200 has ended RBA Day comfortably higher Materials lead gains as iron ore prices rise Small Caps led by Pentanet   The ASX has ended Tuesday higher after the Reserve Bank of Australia kept rates on hold for another month. At 4.15 p...

With the RBA’s interest rates decision due tomorrow, the ASX200’s expected to open marginally higher – the top bank’s two-day meeting gets underway this morning. Our market notched a 2.2 per cent slide last week, and American markets had...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  ASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small cap winners led by American Rare Earths and Appen   The benchmark was shot through the heart by CSL this morning leaving everything else in...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

ASX200 closes 0.9pc higher Property stocks and IT sector enjoy huge day Small caps led by DCL   The Australian sharemarket has lifted strongly on Day Two of Trading in November, the Best Month for Trading Ever. Local investors got stuck r...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

Australian biotechnology company, Memphasys says a $1.3 million research and development tax refund from the ATO will repay a loan and interest, while the net refund will be reinvested as working capital.

Australian biotechnology company, Memphasys says a $1.3 million research and development tax refund from the ATO will repay a loan and interest, while the net refund will be reinvested as working capital.

Benchmark ASX index closes at new 12-month lows Energy and Materials the worst of 9 dipping ASX sectors on Monday Small caps led by CHM, TON   On Monday Aussie markets rediscovered their nadir of the year. No real surprises, since every n...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Just when all looked lost for a group of parent hopefuls in India, a piece of Australian medical technology developed by Memphasys has turned their dreams of the pitter-patter of tiny feet into reality.

Just when all looked lost for a group of parent hopefuls in India, a piece of Australian medical technology developed by Memphasys has turned their dreams of the pitter-patter of tiny feet into reality.

ASX200 is making a strong run into the weekend – up 1.5 per cent with all sectors ahead.  Seismic testing for Woodside’s (WDS) Scarborough gas project off Western Australia’s northern coast has stalled, despite approvals attained in July...

Memphasys’s (MEM) FELIX sperm separation technology has led to 11 successful pregnancies and births in India with 10 more announced today The company’s FELIX product is a compact box device box that separates the largest sperm from seme...

Memphasys reported 10 new live births in India using its Felix system Ramsay Health Care’s credit rating downgraded by Fitch   Memphasys reports 10 new live births in India Reproductive-focused biotech Memphasys (ASX:MEM) has just reporte...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s Top 10 at shortly-before-11-ish, published shortly after I’ve located my reading glasses and wiped the bacon grease off my fingers at the start of each trading day. It highlights the best (and sometimes worst) performing ASX sto...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

 The ASX 200 benchmark has climbed down from highs at lunch to finish on +0.39%. Health Care was well out in front of the market all day, thanks to a chunky bump for CSL. Voltaic Strategic Resources won the Small Caps Cup, rising 22.5% for...

ASX benchmark falls 0.86% for the day, dragged down by bad news from China. Telcos, Energy and InfoTech tried their best, but the overall gloom was too much to fight. Lithium Universe (ASX:LU7) banks a solid market debut as it kicks off i...

Just a week into its pivotal deal with global IVF provider Vitrolife, reproductive biotechnology company Memphasys has already received its first order to put its patented Felix system into clinics in Japan.

Firebrick achieved primary endpoint in Phase 2 Memphasys rise 20pc after distribution deal in Japan Clarity Pharma says ‘pre-targeting’ presents groundbreaking avenue   Firebrick achieves primary endpoint in Phase 2 Firebrick Pharma (ASX:...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX will open lower on Monday Wall Street megacaps mainly fell on Friday This week’s focus will be on US CPI data   The ASX 200 is set to open lower on Monday and extend its 1% loss last week. At 8am AEST, the ASX 200 index futures wa...

Reproductive technology specialist Memphasys has inked an exclusive five-year distribution deal with Vitrolife – a global provider of human IVF medical devices – to sell its patented Felix system in Japan.

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Reproductive biotechnology company Memphasys been granted two new Australian patents for its flagship Felix system, ensuring that the integrity of its IVF treatment device is protected in all markets.

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

The ASX fell this morning and – sadly – just never recovered. It’s down 0.64%. Aside from Happy Times among the lithium players, it’s been a total snoozefest Rubix Resources (ASX:RB6) takes bragging rights with a 41.6% hike for the day  ...

S&P/ASX 200 closes up 0.6%, while the emerging companies index rises 0.86% Austral’s US subsidiary Austral USA awarded a contract worth up to US$3.195 billion from the US Navy Pushpay ceases trading on the ASX and NZX following its $1....

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Despite the materials sector having a tough run today on the back of lower gold, silver and copper prices, many small- and mid-caps in this space are making headway. Dreadnought Resources (DRE) has defined a wide zone of rare earth eleme...

Memphasys (MEM) reports the first live birth of a healthy baby boy in India using its Felix system at the Coimbatore Women’s Hospital Centre However, Memphasys has temporarily suspended sales of Felix into the country following changes...

Aussie shares to extend gains on Monday after a rally in New York EU inflation continues to be at record high Oil prices spiked 7pc as OPEC+ announced cuts   Aussie shares are set to open higher again on Monday, tracking stocks in New Yor...

The ASX is expected to open the new week higher ahead of the much-anticipated RBA rates decision on Tuesday. ASX futures were also up over the weekend. Here are some ASX-listed companies to look out for during Monday’s trade: Dreadnou...

What’s wrong with our tadpoles, gentlemen? According to local fertility expert Prof John Aitken, sperm counts have roughly halved over the last 50 years and about 20 per cent of men shoot blanks. No-one’s sure why, but possible reasons incl...

The ASX extended the week’s losses by falling 0.4% today Star Entertainment Group posted a loss so large it almost defies description Mt Monger has had a fantastic day, up 46.6% after joining the Great Canadian REE Rush   The ASX has fall...

ShareCafeThe Week that Was: February 6-10, 2023 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so,...

ShareCafeMemphasys (ASX: MEM) Felix System Findings Memphasys (ASX: MEM) has announced the first publications of study findings by key opinion leaders of the Felix System. Memphasys (ASX: MEM) Felix System FindingsFinance News Network

ShareCafeASX closes 0.46% lower after RBAs 25 basis point hike by Peter Milios   The Reserve Bank of Australia has raised the official interest rate for the ninth consecutive time to 3.35 per cent. The bank indicated that more rate hikes ma...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] In vitro results from study findings on the Felix system developed by reproductive biotechnology company Memphasys (ASX: MEM) have demonstrated it can outperform conve...

Creso looks to potentially spin out psychedelic subsidiary  Two studies show Memphasys’ Felix reproductive tech outperforms WOA’s Dirty Clean Food brand nabs WHSmith retail deal   Yesterday the big news in the health sector was the Thera...